What Lab Work Do You Need Before Getting a GLP-1 Prescription Online

Most telehealth platforms that prescribe GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound will ask for recent lab work before approving your prescription. The specific tests required vary by provider and your personal health history, but a core set of blood values — primarily related to kidney function, blood sugar, and thyroid health — appears consistently across most reputable online prescribing platforms.

Why Do Telehealth Providers Require Lab Work?

GLP-1 receptor agonists are powerful medications with real contraindications. Before prescribing, a clinician needs to rule out conditions that could make these drugs unsafe for you. According to FDA labeling for both semaglutide and tirzepatide, both medications are contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Kidney disease, pancreatitis history, and uncontrolled diabetes also affect prescribing decisions.

Lab results give providers an objective picture of your baseline health — something a questionnaire alone cannot supply. They also protect both you and the prescribing clinician by documenting that due diligence was done before treatment began.

Which Lab Tests Are Most Commonly Required?

While no universal federal rule mandates a specific lab panel before a GLP-1 prescription, the following tests are routinely requested by telehealth platforms and align with standard clinical practice guidelines from the American Diabetes Association:

• HbA1c (glycated hemoglobin): Measures your average blood sugar over the past two to three months. This is used to confirm or rule out type 2 diabetes and to establish a baseline for monitoring treatment response.
• Fasting blood glucose: A snapshot of your blood sugar after fasting, often ordered alongside HbA1c to assess metabolic status.
• Comprehensive Metabolic Panel (CMP): Includes kidney function markers (creatinine, BUN, eGFR), liver enzymes (ALT, AST), and electrolytes. GLP-1 drugs can affect kidney function, making this panel especially important.
• Lipid panel: Cholesterol and triglyceride levels help assess cardiovascular risk, which is central to the treatment rationale for GLP-1 medications.
• TSH (thyroid-stimulating hormone): FDA labeling for semaglutide and tirzepatide notes an observed risk of thyroid C-cell tumors in rodent studies. While this has not been confirmed in humans, a baseline TSH helps screen for pre-existing thyroid concerns.
• Complete Blood Count (CBC): Some platforms include this to check for anemia or other conditions that could complicate treatment or explain symptoms like fatigue.

What Lab Values Could Delay or Prevent Approval?

Certain results may prompt additional review or outright disqualification, depending on the platform and prescribing clinician:

• eGFR below 30 mL/min/1.73m²: Severe kidney impairment increases the risk of acute kidney injury. FDA labeling for semaglutide notes that dehydration-related kidney problems have been reported, and most platforms will pause or refuse prescribing at this threshold.
• Very high HbA1c (above 10–11%): May indicate poorly controlled diabetes requiring in-person specialist management rather than a telehealth-only approach.
• Elevated liver enzymes (ALT or AST more than 3× normal): Could signal liver disease that warrants further evaluation before starting treatment.
• Elevated amylase or lipase: If a provider orders these, high values may suggest existing pancreatic inflammation, which is a relative contraindication given the reported association between GLP-1 drugs and pancreatitis.
• Abnormal TSH: An undiagnosed or uncontrolled thyroid condition may need to be addressed first.

How Recent Do Your Labs Need to Be?

What If You Don't Have Recent Lab Work?

Not having recent labs is not a dead end. Most telehealth platforms that prescribe GLP-1 medications can either order labs directly through partner laboratory networks (such as Quest Diagnostics or LabCorp) or direct you to a local lab for a draw. Many will send you a lab order digitally, and results are typically returned within two to five business days. Some platforms absorb a basic lab panel into their subscription fee; others charge separately, so confirm this before completing your intake.

If you have a primary care provider, requesting a copy of your most recent labs from their office is often the fastest and least expensive route. Under HIPAA, you are entitled to your own medical records, and most offices can provide them within a few business days.

For more on how telehealth platforms evaluate your overall eligibility — beyond just lab values — see How Telehealth GLP-1 Platforms Decide If You Qualify for a Prescription.

Do Labs Get Repeated During Treatment?

Yes. Initial labs are a baseline, not a one-time requirement. Most prescribing clinicians and platform protocols recommend repeat monitoring at regular intervals once you start a GLP-1 medication:

• HbA1c: Every 3 months initially, then every 6 months once stable, per ADA standards.
• Comprehensive Metabolic Panel: Often repeated at 3 to 6 months to check kidney and liver function as the dose escalates.
• Lipid panel: Annually in most cases, or sooner if baseline results were abnormal.

Ongoing monitoring lets your prescriber catch problems early — for example, a drop in eGFR that might warrant a dose adjustment or temporary discontinuation during illness or hot weather when dehydration risk is higher.

Frequently Asked Questions

The lab requirements described here reflect common clinical practice, but every telehealth platform sets its own protocols, and every clinician exercises individual judgment. Before starting any GLP-1 medication, speak directly with your prescribing clinician about which specific tests they need, how recent those results must be, and how your individual health history might change what is required. Your prescriber is the right person to interpret your results and decide whether treatment is appropriate for you.